Immune-related adverse events and the balancing act of immunotherapy

The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.

Detalles Bibliográficos
Autores principales: Conroy, Michael, Naidoo, Jarushka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2022
Materias:
Comment
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770784/
https://www.ncbi.nlm.nih.gov/pubmed/35046403
http://dx.doi.org/10.1038/s41467-022-27960-2
Descripción
Sumario:The benefit from immune checkpoint inhibitors is tempered by immunologic toxicities, which involve diverse organs, have varying biology, onset time, and severity. Herein, we identify important areas of controversy and open research questions in the field of immune-related toxicity.

Ejemplares similares